Biotech | August 06, 2024
Lupin completes successful Phase 3 trials for Lucentis biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Strong topline growth driven by solid performance across key brands.
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
Subscribe To Our Newsletter & Stay Updated
